Jaana Nevalainen1, Mikko Sairanen2, Heidi Appelblom2, Mika Gissler3, Susanna Timonen4, Markku Ryynänen1. 1. Department of Obstetrics and Gynecology, PL 24, 90100, Oulu University Hospital, Finland. 2. Perkin Elmer, PL 10, 20101, Turku, Finland. 3. National Institute for Health and Welfare, P.O. Box 30, FI-00271, Helsinki, Finland. 4. Department of Obstetrics and Gynecology, PL 52, 20521, Turku University Hospital, Finland.
Abstract
BACKGROUND: Current screening methods for gestational diabetes mellitus (GDM) are insufficient in detecting the risk of GDM in the first trimester of the pregnancy. Recent metabolomic studies have detected altered amino acid and acylcarnitine concentrations in type 2 diabetes (T2D). Because of the similarities between T2D and GDM, the determination of these metabolites may be useful in early screening for GDM. AIM: To evaluate the association between GDM and first-trimester maternal serum concentrations of ten amino acids and 31 acylcarnitines. METHODS: This retrospective case-control study included data from pregnant women screened at Oulu University Hospital between 1.1.2008 and 31.12.2011. A total of 31,146 women participated voluntarily in a first-trimester combined screening (for chromosomal abnormalities). The study population included 69 women who developed GDM during pregnancy and 295 women without diabetes before or after pregnancy. The serum concentrations of ten amino acids and 31 acylcarnitines were analyzed from frozen serum samples taken in the first-trimester screening. Multiple of median (MoM) values were compared between the two groups. RESULTS: In the GDM group, serum levels of arginine were significantly higher (1.13 MoM vs. 0.97 MoM), and those of glycine (0.93 MoM vs. 1.03 MoM) and 3-hydroxy-isovalerylcarnitine (0.86 MoM vs. 1.03 MoM) significantly lower compared to the control group (all p < 0.01). In each case, arginine, glycine, and 3-hydroxy-isovaleryl-carnitine would have detected 46%, 32%, and 39% of GDM cases, with a false-positive rate of 20%. Combining these three metabolites with the first-trimester serum marker pregnancy-associated plasma protein A (PAPP-A) and prior risk (age, BMI, and smoking) achieved a detection rate of 72%. CONCLUSION: There are significant differences in the serum levels of arginine, glycine, and 3-hydroxy-isovalerylcarnitine between controls and women who subsequently develop GDM. These differences were already existent in the first trimester of the pregnancy. The use of metabolites in combination with prior risk and first-trimester PAPP-A represents a reliable method to identify women at risk of GDM.
BACKGROUND: Current screening methods for gestational diabetes mellitus (GDM) are insufficient in detecting the risk of GDM in the first trimester of the pregnancy. Recent metabolomic studies have detected altered amino acid and acylcarnitine concentrations in type 2 diabetes (T2D). Because of the similarities between T2D and GDM, the determination of these metabolites may be useful in early screening for GDM. AIM: To evaluate the association between GDM and first-trimester maternal serum concentrations of ten amino acids and 31 acylcarnitines. METHODS: This retrospective case-control study included data from pregnant women screened at Oulu University Hospital between 1.1.2008 and 31.12.2011. A total of 31,146 women participated voluntarily in a first-trimester combined screening (for chromosomal abnormalities). The study population included 69 women who developed GDM during pregnancy and 295 women without diabetes before or after pregnancy. The serum concentrations of ten amino acids and 31 acylcarnitines were analyzed from frozen serum samples taken in the first-trimester screening. Multiple of median (MoM) values were compared between the two groups. RESULTS: In the GDM group, serum levels of arginine were significantly higher (1.13 MoM vs. 0.97 MoM), and those of glycine (0.93 MoM vs. 1.03 MoM) and 3-hydroxy-isovalerylcarnitine (0.86 MoM vs. 1.03 MoM) significantly lower compared to the control group (all p < 0.01). In each case, arginine, glycine, and 3-hydroxy-isovaleryl-carnitine would have detected 46%, 32%, and 39% of GDM cases, with a false-positive rate of 20%. Combining these three metabolites with the first-trimester serum marker pregnancy-associated plasma protein A (PAPP-A) and prior risk (age, BMI, and smoking) achieved a detection rate of 72%. CONCLUSION: There are significant differences in the serum levels of arginine, glycine, and 3-hydroxy-isovalerylcarnitine between controls and women who subsequently develop GDM. These differences were already existent in the first trimester of the pregnancy. The use of metabolites in combination with prior risk and first-trimester PAPP-A represents a reliable method to identify women at risk of GDM.
Authors: Rhonda Bentley-Lewis; Jennifer Huynh; Grace Xiong; Hang Lee; Julia Wenger; Clary Clish; David Nathan; Ravi Thadhani; Robert Gerszten Journal: Diabetologia Date: 2015-03-07 Impact factor: 10.122
Authors: Judit Bene; Magdolna Márton; Márton Mohás; Zoltán Bagosi; Zoltán Bujtor; Tamás Oroszlán; Beáta Gasztonyi; Istvan Wittmann; Bela Melegh Journal: Ann Nutr Metab Date: 2012-12-28 Impact factor: 3.374
Authors: Dagmar Drogan; Warwick B Dunn; Wanchang Lin; Brian Buijsse; Matthias B Schulze; Claudia Langenberg; Marie Brown; Anna Floegel; Stefan Dietrich; Olov Rolandsson; David C Wedge; Royston Goodacre; Nita G Forouhi; Stephen J Sharp; Joachim Spranger; Nick J Wareham; Heiner Boeing Journal: Clin Chem Date: 2014-12-18 Impact factor: 8.327
Authors: Alena Stancáková; Mete Civelek; Niyas K Saleem; Pasi Soininen; Antti J Kangas; Henna Cederberg; Jussi Paananen; Jussi Pihlajamäki; Lori L Bonnycastle; Mario A Morken; Michael Boehnke; Päivi Pajukanta; Aldons J Lusis; Francis S Collins; Johanna Kuusisto; Mika Ala-Korpela; Markku Laakso Journal: Diabetes Date: 2012-05-02 Impact factor: 9.461
Authors: Ele Ferrannini; Andrea Natali; Stefania Camastra; Monica Nannipieri; Andrea Mari; Klaus-Peter Adam; Michael V Milburn; Gabi Kastenmüller; Jerzy Adamski; Tiinamaija Tuomi; Valeriya Lyssenko; Leif Groop; Walter E Gall Journal: Diabetes Date: 2012-11-16 Impact factor: 9.461
Authors: Denise M Scholtens; Michael J Muehlbauer; Natalie R Daya; Robert D Stevens; Alan R Dyer; Lynn P Lowe; Boyd E Metzger; Christopher B Newgard; James R Bain; William L Lowe Journal: Diabetes Care Date: 2013-08-29 Impact factor: 19.112
Authors: Wei Perng; Brandy M Ringham; Harry A Smith; Gregory Michelotti; Katerina M Kechris; Dana Dabelea Journal: Diabetologia Date: 2019-11-13 Impact factor: 10.122
Authors: Sergey A Krupenko; Shelley A Cole; Ruixue Hou; Karin Haack; Sandra Laston; Nitesh R Mehta; Anthony G Comuzzie; Nancy F Butte; V Saroja Voruganti Journal: Am J Clin Nutr Date: 2022-08-04 Impact factor: 8.472
Authors: Julia Alanen; Heidi Appelblom; Teemu Korpimaki; Heikki Kouru; Mikko Sairanen; Mika Gissler; Markku Ryynanen; Jaana Nevalainen Journal: Arch Gynecol Obstet Date: 2020-07-11 Impact factor: 2.344
Authors: Ionela Mihaela Vladu; Diana Clenciu; Adina Mitrea; Anca Amzolini; Simona Elena Micu; Anda Elena Crisan; Ion Cristian Efrem; Maria Fortofoiu; Mircea Catalin Fortofoiu; Adrian Mita; Anca Barau Alhija; Adina Dorina Glodeanu; Maria Mota Journal: Metabolites Date: 2022-04-22